WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012093127) MODULATORS OF IL-12 AND/OR IL-23 FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/093127    International Application No.:    PCT/EP2012/050066
Publication Date: 12.07.2012 International Filing Date: 04.01.2012
IPC:
C07K 16/18 (2006.01), A61P 25/28 (2006.01)
Applicants: UNIVERSITÄT ZÜRICH [CH/CH]; Rämistr. 71 CH-8006 Zürich (CH) (For All Designated States Except US).
CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN [DE/DE]; Charitéplatz 1 10117 Berlin (DE) (For All Designated States Except US).
BECHER, Burkhard [DE/CH]; (CH) (For US Only).
HEPPNER, Frank [DE/DE]; (DE) (For US Only)
Inventors: BECHER, Burkhard; (CH).
HEPPNER, Frank; (DE)
Agent: SCHULZ JUNGHANS PATENTANWÄLTE; Chausseestraße 5 10115 Berlin (DE)
Priority Data:
11150090.6 04.01.2011 EP
11161991.2 12.04.2011 EP
Title (EN) MODULATORS OF IL-12 AND/OR IL-23 FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE
(FR) MODULATEURS D'IL-12 ET/OU IL-23 POUR LA PRÉVENTION OU LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
Abstract: front page image
(EN)The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like- molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R- β1, IL-12R-β2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided.
(FR)L'invention concerne un anticorps contre p40, IL-12 ou IL-23 pour la prévention ou le traitement de la maladie d'Alzheimer. Elle concerne également des ligands pour la paire d'interleukine 12 ou 23 et son récepteur spécifique, notamment un anticorps, un fragment d'anticorps, une molécule de type anticorps, pour la prévention ou le traitement de la maladie d'Alzheimer. L'invention concerne également un ARN interférent, des modulateurs antisens ou du facteur de transcription de l'expression génique de p19, p35, p40, IL-12R-§1, IL-12R-§2 et/ou IL-23R pour la prévention ou le traitement de la maladie d'Alzheimer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)